Sigachi Industries Limited has informed the Exchange regarding a press release dated January 21, 2026, titled "Sigachi Industries Achieves Key R&D Milestone in Cystic Fibrosis APIs".
SIGACHI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sigachi Industries Limited has shared a press release dated January 21, 2026, announcing that it has achieved a key research and development milestone in Active Pharmaceutical Ingredients (APIs) used for treating Cystic Fibrosis, a serious genetic disorder affecting the lungs and digestive system. The filing itself is an intimation to the stock exchange about this development rather than a financial update, so no revenue, cost, or order-value figures have been disclosed here. The company appears to be expanding its specialty pharma and critical-care API portfolio beyond its traditional excipients business. Investors would need to wait for further details on timelines, regulatory approvals, and commercial partnerships to gauge the scale of this opportunity.
Positive for long-term growth narrative as it signals entry into a high-value, niche therapeutic API segment, but near-term stock impact may be limited since this is a research milestone and not a confirmed commercial order or revenue event.